188 jili cc (The Center Square) – Legislators in Washington, D.C., have taken a number of steps over the past few days to push for insurance and pharmaceutical reforms to be passed before the end of the year. On Wednesday, a bicameral group of Republican and Democrat lawmakers held a press conference discussing the need for pharmacy benefit manager reform to protect small pharmacies across the country and “save lives.” “Whether you are a Republican, Democrat, or an independent, we all want the same thing. We want accessible, affordable, quality health care,” said Rep. Buddy Carter, R-Ga. “We’re not here today to just discuss one bill or to discuss just one patient’s story. We're here because there's broad, bipartisan pharmacy benefit manager, or PBM, reform that is needed to save lives.” Pharmacy benefit managers are the middlemen responsible for managing the drug prices covered by health insurance plans. According to the Harvard Political Review , the problem with pharmacy benefit managers is that they “have vertically integrated with pharmacy chains and health insurers through massive conglomerates.” That then allows them to abuse their power to cut out small pharmacies and increase prices. Carter also signed a letter that was released last week calling on the Department of Justice to dig into the role pharmacy benefit managers played in the opioid epidemic. Reps. Raja Krishnamoorthi, D-Ill., Deborah Ross, D-N.C., and Cliff Benz, R-Ore., all joined him in signing that letter. “The opioid crisis has devastated communities in North Carolina and across the country, and PBMs may have fueled it by prioritizing profits over people,” Ross said on social media . “That’s why I joined a letter calling on the DOJ to investigate their role and hold these bad actors accountable.” The letter looked at recent reports on the largest pharmacy benefit managers, CVS Caremark, Express Scripts, and OptumRx which state that they “colluded and conspired to steer patients towards OxyContin in exchange for $400 million.” OxyContin is a trade name for the narcotic oxycodone hydrochloride, a painkiller available by prescription only. This and the general “lack of transparency” is just one of the many complaints that legislators aired on Wednesday. “My colleagues who are joining me today, Democrats and Republicans ... all recognize that PBMs are decreasing the accessibility, the affordability, and therefore the quality of health care in America,” Carter said. “We have an opportunity, right now, to advance bipartisan legislation that increases reporting requirements, which would heighten transparency and shine a light on the opaque practices of these PBMs.” Carter was also joined by Sen. James Lankford, R-Okla., who is leading the effort to get legislation passed in the U.S. Senate. “This year, we're losing about one pharmacy a day in America,” Lankford said. “We want leadership to be able to take this up and to bring it up in the end-of-year package ... Stop holding up legislation that is bipartisan, bicameral, and solving a problem that Americans need solved.”

In addition to playing time, foreign media have also discussed the impact of LeBron James' workload on his performance in crucial moments of games. While James has a reputation for being a clutch player who thrives under pressure, there have been instances this season where he has appeared fatigued and struggled to deliver in key moments. This has led to debates about whether the Lakers should manage James' minutes more effectively to ensure that he is at his best when it counts.

In the aftermath of this incident, it is imperative that we come together as a society to support and protect one another. We must stand united against those who seek to harm and exploit others, and work towards creating a safer and more secure environment for all. DEADLINE NEXT WEEK: Berger Montague Advises Paragon 28 (NYSE: FNA) Investors to Contact the Firm Before November 29, 20243 Reasons to Buy Domino's Pizza Stock Like There's No Tomorrow

Moreover, Zelensky's rejection of Trump's proposal underscores the importance of a comprehensive and inclusive approach to conflict resolution. Any lasting peace in Eastern Ukraine must address the underlying causes of the conflict, including political grievances, economic disparities, and social inequalities. The voices and concerns of all stakeholders, including civilians living in the conflict-affected areas, must be taken into consideration to ensure a sustainable and just resolution.The much-anticipated film "Botticelli, Florence, and the Medici Family" is now available for pre-sale! Set to hit theaters on December 13th, this cinematic masterpiece promises to take viewers on a mesmerizing journey through the life and art of one of the greatest artists of the Italian Renaissance, Sandro Botticelli.The Holy Altar combination, consisting of the talented players Ling Yao and Zhang Wei, captured the hearts of badminton fans worldwide with their dynamic playing style and unwavering dedication to the sport. The pair's synergy on the court was undeniable, as they seamlessly coordinated their movements and strategies to outclass their opponents in every match.

2. **Volkswagen**

Apraglutide is under clinical development by and currently in Phase III for Short Bowel Syndrome. According to GlobalData, Phase III drugs for Short Bowel Syndrome have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Apraglutide overview FE-203799) is under development for the treatment of short bowel syndrome intestinal failure (SBS-IF) and gastrointestinal acute graft versus host disease (GVHD). It is administered through subcutaneous route in the form of powder and solution for injection. The drug candidate is a long-acting synthetic peptide analogue of glucagon-like-peptide-2 (GLP-2) which acts on GLP-2 receptor. It is developed by using peptide technology. It was also under development for the treatment of chemotherapy-induced gastro-intestinal mucositis. Ironwood Pharmaceuticals overview (Ironwood) is a healthcare company engaged in the discovery, development, and commercialization of human therapeutics and innovative gastrointestinal product opportunities. The company’s pipeline products include linaclotide, and vascular or fibrotic programs. Ironwood offers its products under two brands- Linzess and Constella. The company generates a pipeline of early development candidates and discovery research programs in various therapeutic areas which include gastrointestinal (GI), central nervous system (CNS) and allergic disorders. The company’s portfolio includes CNP-104 and IW-3300. It has strategic partnerships with leading pharmaceutical companies such as Inc, for the development and commercialization of linaclotide across the globe. The company operates in the US and Switzerland. Ironwood is headquartered in Boston, Massachusetts, the US. For a complete picture of Apraglutide’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .Lions head into NFC title game rematch vs. 49ers seeking top seed more than revenge

Georgia is turning to backup Gunner Stockton at quarterback in CFP quarterfinal against Irish

( MENAFN - GetNews) Meetion brings innovation with ergonomic office solutions and tri-mode gaming gear. Meetion, a famous brand of gaming keyboards, mice, and computer accessories, has announced its participation in CES 2025. At the exhibition, Meetion will showcase its innovative gaming and office product lines at Booth #32135, LVCC South Hall 1, during the January 7–10, 2025, Las Vegas event. With a global target market, Meetion's most recent products offer unparalleled user experiences for both professionals and gamers by fusing state-of-the-art technology, ergonomic designs, and outstanding value. Meetion: Where Innovation Meets Excellence Meetion is committed to comprehending and satisfying customer needs, which is why it keeps emphasizing user-centric designs. The company guarantees that its peripherals boost productivity and provide the best possible gaming experience by solving market pain points and improving products based on input from users. Highlighted Products: 1. Tri-Mode Gaming Mouse Series (GW24/GW32/GW33/GW38/GW39) The Tri-Mode Gaming Mouse series redefines precision and performance with: 2. Tri-Mode Gaming Headset Series (BTH011/BTH012/BTH013/BTH014) The ultimate immersive audio solution for gamers features: 3. Tri-Mode Gaming Mechanical Keyboard Series (MK12/MK14) Pushing the boundaries of innovation, the Tri-Mode Gaming Keyboard features: 4. Dual-Mode Apple Keyboard and Mouse Set (iKey C210/iKey C230) Designed for professionals, this sleek and minimalist set offers: 5. Wireless Ergonomic Set (DirectorA/DirectorB/DirectorC2/DirectorD) Prioritizing health and comfort, Meetion's ergonomic solution includes: Why Meetion Stands Out? Exhibition Details: About Meetion Leading the way in computer accessories worldwide, Meetion is renowned for producing cutting-edge, reasonably priced goods that improve gaming and work environments. With the motto "Meetion's World, World's Meetion," the business concentrates on comprehending customer needs and developing goods that blend cutting-edge technology, ergonomic design, and outstanding value. Learn more at: For more details, contact Meetion at ... or call +86 75523579736 Meetion is a global leader in ergonomic and gaming peripherals, offering high-quality products designed for performance and user comfort. Established in 2013, the company serves customers in over 50 countries with a diverse range of cutting-edge solutions. MENAFN23122024003238003268ID1109025454 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

SANTA CLARA, Calif. (AP) — Dan Campbell stood at the podium after Detroit blew a 17-point lead to San Francisco in last season's NFC title game and talked about how that might have been the Lions' only shot at reaching the Super Bowl. The coach knew how difficult it would be to maintain that high level of play through injuries, attrition and with a target on their back as a top contender in the NFC. Eleven months later as Campbell and the Lions prepare to return to Levi's Stadium for the first time since that loss , that has proved to be prophetic — for San Francisco instead of Detroit. The Lions (13-2) head into the rematch Monday night with the inside track at the top seed in the NFC playoffs, while the 49ers (6-9) have already been eliminated from postseason contention . The element of revenge for last season's 34-31 loss is secondary for Detroit, considering what's on the line the last two weeks of the season. The Lions can clinch the top seed in the NFC by winning their final two games or with a win against the Niners if Minnesota loses to Green Bay on Sunday. “Anytime we lose, the thought of losing is going to motivate you to not want to lose again, particularly with where you were at,” Campbell said. “So, that’s always going to bring its own level of motivation to it. But this is where we’re at in the season, we know that we need another win, we understand where we’re at in the division and the NFC, so I think it’s all encompassing.” While the Lions have no need to search for motivation, that's not the case for the 49ers, who are playing out the string of a lost season after making losing back-to-back NFC title games in 2021-22 and the Super Bowl last season. A run of injuries to key players like Christian McCaffrey, Trent Williams, Nick Bosa and Brandon Aiyuk, combined with inconsistent play all season have led to the 49ers having nothing to play for in the final two games. “It’s obviously not where you want to be this time of year,” Bosa said. "It’s different, especially watching where we’re at last year against this team. Just that feeling of December, January football is a feeling that I’ve gotten used to being really competitive and being in the mix. I think we’re doing a good job of staying engaged and obviously this is our job, so we’re going to finish it strong. Go ing deep Detroit’s faith in Jameson Williams is paying off, taking advantage of his game-breaking abilities with big plays. Jared Goff heaved an 82-yard touchdown pass over Williams’ shoulders and into his hands in last week’s win at Chicago. Earlier this season, Goff threw 70-, 64- and 52-yard passes for scores to the third-year receiver. “We work on it a ton, him and I do, and it’s a testament to him,” Goff said. “He’s asking for it. He wants that work, and I’m more than happy to give it to him during the week. It’s good. Our connection continues to grow. He’s obviously one of the best deep threats in our league, even when it’s not perfect.” Makeshift line The 49ers head into the game scrambling to put together an offensive line. Williams has been out for more than a month with an ankle injury and his backup at left tackle, Jaylon Moore, is now sidelined by a quadriceps injury. Left guard Aaron Banks injured his knee last week, while his backup Ben Bartch is already out with an ankle injury. That will leave the Niners with two third-stringers protecting Brock Purdy. But Shanahan said he isn’t thinking of sitting Purdy to protect him. “People deal with that throughout the year on other weeks, too,” he said. “I mean, we’ve got a football team. We’ve got to go out and we’ve got two games here and we’ve got to see what guys we can put out there and whatever we do we’re going to put a game plan together to, as best as we can to give us a chance to win.” Bag of tricks Lions offensive coordinator Ben Johnson, who may have a chance for the second straight offseason to be an NFL head coach, routinely pulls off trick plays and his latest was a doozy. Goff intentionally stumbled after taking a snap and Jahmyr Gibbs went to the ground as their teammates yelled, “fumble,” to fool the Bears on a 21-yard touchdown pass to Sam LaPorta. “Those make you feel good because everybody is invested in it,” Campbell said. “It’s fun. It’s different. It’s sound. “I know it sounds crazy, but it’s sound.” Just for kicks San Francisco kicker Jake Moody is having a rough second season after being drafted in the third round a year ago. Moody has missed seven field goals this season, including a 41-yarder last week at Miami. Moody is just 10 for 16 since coming back from a high ankle sprain in his kicking foot, but Shanahan said he still has confidence in him. “I still feel the same about him, that I believe he’ll be our guy,” Shanahan said. "I mean everyone’s got to perform and do things like that. I think he has had a tough year. Before his high ankle sprain, he missed one. ... I think he was 12 of 13 before that, so I thought he was doing really well." AP Sports Writer Larry Lage contributed to this report. AP NFL: https://apnews.com/hub/nfl